ID

42540

Descripción

Study ID: 105874 Clinical Study ID: 105874 Study Title: Bridging Safety & Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine RTS,S/AS01E (0.5 mL Dose) to RTS,S/AS02D (0.5 mL Dose) Administered IM According to a 0, 1, 2-Month Schedule in Gabonese Children Aged 18 Months to 4 Years Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00307021 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049 Trade Name: N/A Study Indication: Malaria ODM derived from https://clinicaltrials.gov/ct2/show/NCT00307021. A Phase II randomized, double-blind bridging study of the safety and immunogenicity of GlaxoSmithKline Plasmodium falciparum malaria vaccine RTS,S/AS01E (0.5 mL dose) to RTS,S/AS02D (0.5 mL dose) administered IM according to a 0, 1, 2- month vaccination schedule in children aged 18 months to 4 years living in Gabon. Clinical Visits: This study has a total of 7 visits. Visit 1 = Screening, Visits 2-6 are during the double-blind phase (Month 0-3) and Visit 7 is during the single-blind phase (Month 4-14). Vaccine administration takes place during visits 2, 4, and 5 (Visit 2 = Dose 1; Visit 4 = Dose 2; Visit 5 = Dose 3). Field-worker Visits: During the double-blind phase, clinical visits are accompanied by daily field-worker visits subsequent to each vaccine administration visit. Additional field-worker visits also take place during months 4 to 13 of the single-blind phase. For all subjects enrolled, please complete the study conclusion form. The study conclusion should be documented subsequently to clinical visit 7 in separate forms for the double-blind and the single-blind phase respectively. The 'Status of Treatment Blind' item group only needs to be completed within the form for the double-blind phase. Note that informed consent has to be obtained prior to any study procedure.

Link

https://clinicaltrials.gov/ct2/show/NCT00307021

Palabras clave

Versiones (1)
  1. 24/8/21 24/8/21 -
Titular de derechos de autor

GlaxoSmithKline

Subido en

24 de agosto de 2021

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Safety & Immunogenicity of two GSK Biologicals' Candidate Malaria Vaccines in young children, NCT00307021

Inglés

Study Conclusion

1 formularios  
  1. StudyEvent: ODM
    1. Study Conclusion
Administrative Documentation
Descripción

Administrative Documentation

Alias
UMLS CUI-1
C1320722
Date of visit
Descripción

Date of visit

Tipo de datos

date

Alias
UMLS CUI [1]
C1320303
Subject number
Descripción

Subject number

Tipo de datos

integer

Alias
UMLS CUI [1]
C2348585
Study phase
Descripción

Please specify the study phase for which the form is filled in.

Tipo de datos

integer

Alias
UMLS CUI [1,1]
C0205390
UMLS CUI [1,2]
C2603343
Occurrence of Serious Adverse Events
Descripción

Occurrence of Serious Adverse Events

Alias
UMLS CUI-1
C1519255
Did the subject experience any Serious Adverse Event during the study period?
Descripción

Serious adverse event during clinical trial period

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1519255
UMLS CUI [1,2]
C0347984
UMLS CUI [1,3]
C2347804
If yes, specify total number of SAEs.
Descripción

Serious adverse event during clinical trial period count specification

Tipo de datos

integer

Alias
UMLS CUI [1,1]
C1519255
UMLS CUI [1,2]
C0347984
UMLS CUI [1,3]
C2347804
UMLS CUI [1,4]
C0750480
UMLS CUI [1,5]
C1521902
Status of Treatment Blind
Descripción

Status of Treatment Blind

Alias
UMLS CUI-1
C0749659
UMLS CUI-2
C2347038
Was the treatment blind broken during the study?
Descripción

Only to be completed for the double-blind phase version of the form. If yes, complete date and tick one reason in the following items.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3897431
UMLS CUI [1,2]
C0347984
UMLS CUI [1,3]
C2347804
Date of breaking treatment blind
Descripción

Subject unblinding event record date

Tipo de datos

date

Alias
UMLS CUI [1,1]
C3897431
UMLS CUI [1,2]
C0011008
Reason for breaking treatment blind
Descripción

Please tick one reason. If [9] other, please specify in the following item. Also complete Non-Serious Adverse Event section or a Serious Adverse Event report as appropriate.

Tipo de datos

text

Alias
UMLS CUI [1,1]
C3897431
UMLS CUI [1,2]
C0566251
UMLS CUI [1,3]
C0205225
If other, please specify
Descripción

Subject unblinding event record other reason to specify

Tipo de datos

text

Alias
UMLS CUI [1,1]
C3897431
UMLS CUI [1,2]
C0566251
UMLS CUI [1,3]
C0205394
UMLS CUI [1,4]
C1521902
Elimination Criteria
Descripción

Elimination Criteria

Alias
UMLS CUI-1
C0680251
Did any elimination criteria become applicable during the study?
Descripción

Elimination criteria during clinical trial period

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C0347984
UMLS CUI [1,3]
C2347804
If yes, please specify.
Descripción

Elimination criteria to specify

Tipo de datos

text

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1521902
Was the subject withdrawn from the study?
Descripción

For the double-blind phase: Is the subject withdrawn from the double-blind phase? (A subject is withdrawn from the interim analysis if he/she did not come for the doublie blind phase - interim analysis timepoint visit.)

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0422727
If yes, indicate the major reason for withdrawal.
Descripción

Please tick one box only. If serious adverse event [SAE], please complete and submit SAE report.

Tipo de datos

text

Alias
UMLS CUI [1,1]
C0422727
UMLS CUI [1,2]
C0566251
UMLS CUI [1,3]
C0205225
If death [DEA], please specify SAE number.
Descripción

Death-related serious adverse event number to specify

Tipo de datos

integer

Alias
UMLS CUI [1,1]
C1705232
UMLS CUI [1,2]
C1519255
UMLS CUI [1,3]
C0237753
UMLS CUI [1,4]
C1521902
If serious adverse event [SAE], please specify SAE number.
Descripción

Serious adverse event number to specify

Tipo de datos

integer

Alias
UMLS CUI [1,1]
C1519255
UMLS CUI [1,2]
C0237753
UMLS CUI [1,3]
C1521902
If protocol violation [PTV], please specify.
Descripción

Protocol violation to specify

Tipo de datos

text

Alias
UMLS CUI [1,1]
C1709750
UMLS CUI [1,2]
C1521902
If other [OTH], please specify.
Descripción

Withdrawal other reason to specify

Tipo de datos

text

Alias
UMLS CUI [1,1]
C0422727
UMLS CUI [1,2]
C0566251
UMLS CUI [1,3]
C0205394
UMLS CUI [1,4]
C1521902
If subject was withdrawn from the study, indicate who made the decision.
Descripción

Withdrawal decision maker

Tipo de datos

text

Alias
UMLS CUI [1,1]
C0422727
UMLS CUI [1,2]
C0679006
If subject was withdrawn from the study, indicate the date of the last contact.
Descripción

Withdrawal date of last contact

Tipo de datos

date

Alias
UMLS CUI [1,1]
C0422727
UMLS CUI [1,2]
C0805839
If subject was withdrawn from the study, was the subject in good condition at date of last contact?
Descripción

If no, please give details in Adverse Events section.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0422727
UMLS CUI [1,2]
C1142435
UMLS CUI [1,3]
C0805839
I confirm that I have reviewed the data in this Case Report Form for this subject. All information entered by myself or my colleagues is, to the best of my knowledge, complete and accurate, as of the date below.
Descripción

I confirm that I have reviewed the data in this Case Report Form for this subject. All information entered by myself or my colleagues is, to the best of my knowledge, complete and accurate, as of the date below.

Alias
UMLS CUI-1
C2346576
Investigator's signature
Descripción

Investigator signature

Tipo de datos

text

Alias
UMLS CUI [1]
C2346576
Printed investigator's name
Descripción

Investigator name

Tipo de datos

text

Alias
UMLS CUI [1]
C2826892
Date
Descripción

Investigator signature date

Tipo de datos

date

Alias
UMLS CUI [1,1]
C2346576
UMLS CUI [1,2]
C0011008
Volver a la parte superior de la página

Similar models

Study Conclusion

1 formularios
  1. StudyEvent: ODM
    1. Study Conclusion
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Administrative Documentation
C1320722 (UMLS CUI-1)
Date of visit
Item
Date of visit
date
C1320303 (UMLS CUI [1])
Subject number
Item
Subject number
integer
C2348585 (UMLS CUI [1])
Item
Study phase
integer
C0205390 (UMLS CUI [1,1])
C2603343 (UMLS CUI [1,2])
Study phase
Code List
Study phase
CL Item
double-blind phase (1)
(Comment:en)
CL Item
single-blind phase (2)
(Comment:en)
Item Group
Occurrence of Serious Adverse Events
C1519255 (UMLS CUI-1)
Serious adverse event during clinical trial period
Item
Did the subject experience any Serious Adverse Event during the study period?
boolean
C1519255 (UMLS CUI [1,1])
C0347984 (UMLS CUI [1,2])
C2347804 (UMLS CUI [1,3])
Serious adverse event during clinical trial period count specification
Item
If yes, specify total number of SAEs.
integer
C1519255 (UMLS CUI [1,1])
C0347984 (UMLS CUI [1,2])
C2347804 (UMLS CUI [1,3])
C0750480 (UMLS CUI [1,4])
C1521902 (UMLS CUI [1,5])
Item Group
Status of Treatment Blind
C0749659 (UMLS CUI-1)
C2347038 (UMLS CUI-2)
Subject unblinding event record during clinical trial period
Item
Was the treatment blind broken during the study?
boolean
C3897431 (UMLS CUI [1,1])
C0347984 (UMLS CUI [1,2])
C2347804 (UMLS CUI [1,3])
Subject unblinding event record date
Item
Date of breaking treatment blind
date
C3897431 (UMLS CUI [1,1])
C0011008 (UMLS CUI [1,2])
Item
Reason for breaking treatment blind
text
C3897431 (UMLS CUI [1,1])
C0566251 (UMLS CUI [1,2])
C0205225 (UMLS CUI [1,3])
Subject unblinding event record reason and justification
Code List
Reason for breaking treatment blind
CL Item
Medical emergency requiring identification of investigational product for further treatments ([1])
CL Item
Other ([9])
Subject unblinding event record other reason to specify
Item
If other, please specify
text
C3897431 (UMLS CUI [1,1])
C0566251 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C1521902 (UMLS CUI [1,4])
Item Group
Elimination Criteria
C0680251 (UMLS CUI-1)
Elimination criteria during clinical trial period
Item
Did any elimination criteria become applicable during the study?
boolean
C0680251 (UMLS CUI [1,1])
C0347984 (UMLS CUI [1,2])
C2347804 (UMLS CUI [1,3])
Elimination criteria to specify
Item
If yes, please specify.
text
C0680251 (UMLS CUI [1,1])
C1521902 (UMLS CUI [1,2])
Patient withdrawn from trial
Item
Was the subject withdrawn from the study?
boolean
C0422727 (UMLS CUI [1])
Item
If yes, indicate the major reason for withdrawal.
text
C0422727 (UMLS CUI [1,1])
C0566251 (UMLS CUI [1,2])
C0205225 (UMLS CUI [1,3])
Withdrawal reason and justification primary
Code List
If yes, indicate the major reason for withdrawal.
CL Item
Death ([DEA])
CL Item
Serious adverse event ([SAE])
CL Item
Protocol violation ([PTV])
CL Item
Consent withdrawal, not due to an adverse event ([CWS])
CL Item
Migrated / moved from the study area ([MIG])
CL Item
Lost to follow-up ([LFU])
CL Item
Other ([OTH])
Death-related serious adverse event number to specify
Item
If death [DEA], please specify SAE number.
integer
C1705232 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
C0237753 (UMLS CUI [1,3])
C1521902 (UMLS CUI [1,4])
Serious adverse event number to specify
Item
If serious adverse event [SAE], please specify SAE number.
integer
C1519255 (UMLS CUI [1,1])
C0237753 (UMLS CUI [1,2])
C1521902 (UMLS CUI [1,3])
Protocol violation to specify
Item
If protocol violation [PTV], please specify.
text
C1709750 (UMLS CUI [1,1])
C1521902 (UMLS CUI [1,2])
Withdrawal other reason to specify
Item
If other [OTH], please specify.
text
C0422727 (UMLS CUI [1,1])
C0566251 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C1521902 (UMLS CUI [1,4])
Item
If subject was withdrawn from the study, indicate who made the decision.
text
C0422727 (UMLS CUI [1,1])
C0679006 (UMLS CUI [1,2])
Trial Screen Failure | withdrawal before randomization | withdrawal before vaccination
Code List
If subject was withdrawn from the study, indicate who made the decision.
CL Item
Investigator ([I])
CL Item
Parents/Guardians ([P])
Withdrawal date of last contact
Item
If subject was withdrawn from the study, indicate the date of the last contact.
date
C0422727 (UMLS CUI [1,1])
C0805839 (UMLS CUI [1,2])
Withdrawal general physical condition date last contact
Item
If subject was withdrawn from the study, was the subject in good condition at date of last contact?
boolean
C0422727 (UMLS CUI [1,1])
C1142435 (UMLS CUI [1,2])
C0805839 (UMLS CUI [1,3])
Item Group
I confirm that I have reviewed the data in this Case Report Form for this subject. All information entered by myself or my colleagues is, to the best of my knowledge, complete and accurate, as of the date below.
C2346576 (UMLS CUI-1)
Investigator signature
Item
Investigator's signature
text
C2346576 (UMLS CUI [1])
Investigator name
Item
Printed investigator's name
text
C2826892 (UMLS CUI [1])
Investigator signature date
Item
Date
date
C2346576 (UMLS CUI [1,1])
C0011008 (UMLS CUI [1,2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial